Galectin Therapeutics (NASDAQ:GALT) Receives Neutral Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Galectin Therapeutics (NASDAQ:GALT) in a research note published on Friday,Benzinga reports.

Separately, StockNews.com upgraded Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th.

Galectin Therapeutics Price Performance

Shares of Galectin Therapeutics stock opened at $1.15 on Friday. Galectin Therapeutics has a 52-week low of $0.73 and a 52-week high of $4.27. The firm has a market capitalization of $72.18 million, a PE ratio of -1.58 and a beta of 0.69. The company’s fifty day moving average price is $2.34 and its two-hundred day moving average price is $2.43.

Insider Transactions at Galectin Therapeutics

In other Galectin Therapeutics news, CFO Jack W. Callicutt sold 40,000 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.89, for a total transaction of $35,600.00. Following the transaction, the chief financial officer now directly owns 7,614 shares in the company, valued at approximately $6,776.46. This represents a 84.01 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Joel Lewis sold 56,000 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $0.89, for a total transaction of $49,840.00. Following the sale, the chief executive officer now directly owns 897,012 shares of the company’s stock, valued at approximately $798,340.68. This trade represents a 5.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 15,500 shares of company stock valued at $23,000 and sold 109,654 shares valued at $97,456. Company insiders own 50.10% of the company’s stock.

Institutional Trading of Galectin Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Marshall Wace LLP acquired a new stake in shares of Galectin Therapeutics during the second quarter worth $43,000. Rhumbline Advisers acquired a new position in shares of Galectin Therapeutics during the 2nd quarter worth about $44,000. Gladstone Institutional Advisory LLC bought a new stake in shares of Galectin Therapeutics in the 3rd quarter valued at about $60,000. Barclays PLC raised its position in shares of Galectin Therapeutics by 309.0% in the 3rd quarter. Barclays PLC now owns 28,587 shares of the company’s stock valued at $79,000 after acquiring an additional 21,598 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Galectin Therapeutics by 161.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 30,628 shares of the company’s stock worth $84,000 after acquiring an additional 18,907 shares during the last quarter. Institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.